Xian Y, Xu H, O’Brien EC, et al. - In this observational study of 11,662 individuals with atrial fibrillation (AF) who had had an ischemic stroke and were anticoagulation naive, experts investigated the clinical efficiency of direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, or apixaban) vs warfarin following ischemic stroke in individuals with AF. A total of 4,041 were discharged with DOACs and 7,621 with warfarin. Except for the National Institutes of Health Stroke Scale scores, baseline features were comparable among groups. During the first year postdischarge, individuals discharged with DOACs (vs warfarin) had more days at home and were less prone to encounter major adverse cardiovascular events. Fewer deaths, all-cause readmissions, cardiovascular readmissions, hemorrhagic strokes, and hospitalizations with bleeding were seen in individuals who were receiving DOACs, there were however there was a greater risk of gastrointestinal bleeding. Hence, in individuals with acute ischemic stroke and AF, DOAC use at discharge was related to superior long-term outcomes in regard to warfarin.